212 related articles for article (PubMed ID: 23599152)
1. NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.
Hemminger JA; Iwenofu OH
Mod Pathol; 2013 Sep; 26(9):1204-10. PubMed ID: 23599152
[TBL] [Abstract][Full Text] [Related]
2. [Pathological significance of NY-ESO-1 expression in the diagnosis of myxoid liposarcoma].
Hei SM; Wei HJ; Chen H; Wang JG
Zhonghua Bing Li Xue Za Zhi; 2019 Mar; 48(3):225-230. PubMed ID: 30831650
[No Abstract] [Full Text] [Related]
3. The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.
Hemminger JA; Ewart Toland A; Scharschmidt TJ; Mayerson JL; Kraybill WG; Guttridge DC; Iwenofu OH
Mod Pathol; 2013 Feb; 26(2):282-8. PubMed ID: 22936067
[TBL] [Abstract][Full Text] [Related]
4. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.
Pollack SM; Jungbluth AA; Hoch BL; Farrar EA; Bleakley M; Schneider DJ; Loggers ET; Rodler E; Eary JF; Conrad EU; Jones RL; Yee C
Cancer; 2012 Sep; 118(18):4564-70. PubMed ID: 22359263
[TBL] [Abstract][Full Text] [Related]
5. Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.
Iura K; Kohashi K; Hotokebuchi Y; Ishii T; Maekawa A; Yamada Y; Yamamoto H; Iwamoto Y; Oda Y
J Pathol Clin Res; 2015 Jul; 1(3):144-59. PubMed ID: 27499900
[TBL] [Abstract][Full Text] [Related]
6. The utility of fluorescence in situ hybridization (FISH) in the diagnosis of myxoid soft tissue neoplasms.
Downs-Kelly E; Goldblum JR; Patel RM; Weiss SW; Folpe AL; Mertens F; Hartke M; Tubbs RR; Skacel M
Am J Surg Pathol; 2008 Jan; 32(1):8-13. PubMed ID: 18162764
[TBL] [Abstract][Full Text] [Related]
7. MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1.
Iura K; Kohashi K; Ishii T; Maekawa A; Bekki H; Otsuka H; Yamada Y; Yamamoto H; Matsumoto Y; Iwamoto Y; Oda Y
Virchows Arch; 2017 Sep; 471(3):383-392. PubMed ID: 28744588
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.
Shurell E; Vergara-Lluri ME; Li Y; Crompton JG; Singh A; Bernthal N; Wu H; Eilber FC; Dry SM
Oncotarget; 2016 Nov; 7(45):72860-72867. PubMed ID: 27655679
[TBL] [Abstract][Full Text] [Related]
9. NY-ESO-1 expression in synovial sarcoma and other mesenchymal tumors: significance for NY-ESO-1-based targeted therapy and differential diagnosis.
Lai JP; Robbins PF; Raffeld M; Aung PP; Tsokos M; Rosenberg SA; Miettinen MM; Lee CC
Mod Pathol; 2012 Jun; 25(6):854-8. PubMed ID: 22388761
[TBL] [Abstract][Full Text] [Related]
10. Nuclear expression of DDIT3 distinguishes high-grade myxoid liposarcoma from other round cell sarcomas.
Baranov E; Black MA; Fletcher CDM; Charville GW; Hornick JL
Mod Pathol; 2021 Jul; 34(7):1367-1372. PubMed ID: 33731886
[TBL] [Abstract][Full Text] [Related]
11. NY-ESO-1 as a diagnostic and prognostic marker for myxoid liposarcoma.
Jo U; Roh J; Song MJ; Cho KJ; Kim W; Song JS
Am J Transl Res; 2022; 14(2):1268-1278. PubMed ID: 35273728
[TBL] [Abstract][Full Text] [Related]
12. NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.
Endo M; de Graaff MA; Ingram DR; Lim S; Lev DC; Briaire-de Bruijn IH; Somaiah N; Bovée JV; Lazar AJ; Nielsen TO
Mod Pathol; 2015 Apr; 28(4):587-95. PubMed ID: 25412843
[TBL] [Abstract][Full Text] [Related]
13. Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.
Hemminger JA; Toland AE; Scharschmidt TJ; Mayerson JL; Guttridge DC; Iwenofu OH
Mod Pathol; 2014 Sep; 27(9):1238-45. PubMed ID: 24457462
[TBL] [Abstract][Full Text] [Related]
14. Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia.
Orvieto E; Furlanetto A; Laurino L; Dei Tos AP
Semin Diagn Pathol; 2001 Nov; 18(4):267-73. PubMed ID: 11757867
[TBL] [Abstract][Full Text] [Related]
15. ERG expression in chondrogenic bone and soft tissue tumours.
Shon W; Folpe AL; Fritchie KJ
J Clin Pathol; 2015 Feb; 68(2):125-9. PubMed ID: 25378537
[TBL] [Abstract][Full Text] [Related]
16. Detection of TLS/FUS-CHOP fusion transcripts in myxoid and round cell liposarcomas by nested reverse transcription-polymerase chain reaction using archival paraffin-embedded tissues.
Hisaoka M; Tsuji S; Morimitsu Y; Hashimoto H; Shimajiri S; Komiya S; Ushijima M
Diagn Mol Pathol; 1998 Apr; 7(2):96-101. PubMed ID: 9785008
[TBL] [Abstract][Full Text] [Related]
17. Cytogenetic and molecular genetic analyses of liposarcoma and its soft tissue simulators: recognition of new variants and differential diagnosis.
Meis-Kindblom JM; Sjögren H; Kindblom LG; Peydró-Mellquist A; Röijer E; Aman P; Stenman G
Virchows Arch; 2001 Aug; 439(2):141-51. PubMed ID: 11561754
[TBL] [Abstract][Full Text] [Related]
18. DDIT3 Immunohistochemistry Is a Useful Tool for the Diagnosis of Myxoid Liposarcoma.
Scapa JV; Cloutier JM; Raghavan SS; Peters-Schulze G; Varma S; Charville GW
Am J Surg Pathol; 2021 Feb; 45(2):230-239. PubMed ID: 32815829
[TBL] [Abstract][Full Text] [Related]
19. [Myxoid tumors of deep soft tissues].
Labonté S
Ann Pathol; 2015 Jan; 35(1):3-14. PubMed ID: 25533917
[TBL] [Abstract][Full Text] [Related]
20. Primary retroperitoneal myxoid/round cell liposarcoma is a nonexisting disease: an immunohistochemical and molecular biological analysis.
de Vreeze RS; de Jong D; Tielen IH; Ruijter HJ; Nederlof PM; Haas RL; van Coevorden F
Mod Pathol; 2009 Feb; 22(2):223-31. PubMed ID: 18820664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
